|
详细内容
|
Tyrphostin AG879 is a tyrosine kinase inhibitor that inhibits the phosphorylation of TrKA, but not TrKB and TrKC. Tyrphostin AG879 is also a ErbB2 kinase inhibitor, has at least 500-fold higher selectivity to ErbB2 than EGFR (IC50 > 500 μmol/L). The IC50 of tyrphostinAG879 against ErbB2 is 1 μmol/L [1].
In vitro: AG 879 has been widely used as a Tyr kinase inhibitor specific for ErbB2 and FLK-1, a VEGF receptor. The IC50 value for ErbB2 and FLK-1 was approximately 1 μM. AG 879 at 10 nM blocked the specific interaction between the Tyr-kinase ETK and PAK1 (a CDC42/Rac-dependent Ser/Thr kinase) in cell culture. AG 879 (10 nM) showed no inhibitory effects on the purified ETK and PAK1 directly in vitro, suggesting that this drug blocked the ETK-PAK1 pathway by targeting the highly sensitive kinase upstream of ETK. Src was insensitive to AG 879. FAK was inhibited by 100 nM AG 879, but not by 10 nM AG879 [2]. AG 879 inhibited proliferation of human breast cancer cells through an effect involving inhibition of MAP kinase activation. AG 879 markedly inhibited the expression of the RAF-1 gene, which encoded an upstream MAPKKK. Additionally, AG 879 inhibited the expression of HER-2[3]. Treatment with AG879 (20 μM) dramatically decreased proliferation with a variable increase in apoptosis in Cell lines from human leiomyosarcoma (HTB-114, HTB-115, HTB-88), rhabdomyosarcoma (HTB-82, TE-671), prostatic adenocarcinoma (PC-3), acute promyelocytic leukemia (HL-60) and histiocytic lymphoma (U-937) [4].
In vivo: In athymic NOD/SCID mice grafted with HTB-114 or HL-60, administration of AG879 at 2 mg induced a decrease in cancer growth [4]. AG 879 administration (20 mg/kg) kept 50% of mice absolutely free of RAS-induced sarcomas. In the nude mice carrying v-Ha-RAS transformed NIH 3T3 cells, AG 879 dramatically reduced the size of the growing sarcomas [5].
|